Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab preconditioning with blinatumomab in relapsed/refractory Ph-negative B-cell ALL
KCT0005350Phase 2Not yet recruiting
- Sponsor
- Amgen
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Amgen. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
rituximabblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on KCT0005350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005350.